The purpose of this study is to determine the appropriate regimen of GSK HRV vaccine for concomitant administration with EPI vaccines to infants in South Africa.

Inclusion Criteria:

• Healthy infants born after a normal gestation period (>=36 weeks), between 5 and 10 weeks of age at Dose 1 with confirmed negative HIV status of the subject's mother.
• Written informed consent was obtained from the parent/guardian of the subject before study entry.

Exclusion Criteria:

• History of allergic disease/polio disease,
• Confirmed or suspected immunosuppressive or immunodeficient condition,
• Clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator,
• Received treatment prohibited by the protocol.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.